Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Blood (2012) 120 (16): 3222–3228.

https://doi.org/10.1182/blood-2012-04-423095

Published: 2012

Journal Articles

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

Blood (2011) 117 (18): 4716–4725.

https://doi.org/10.1182/blood-2010-08-302950

Published: 2011

Includes: Supplemental data

Journal Articles

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Blood (2011) 117 (8): 2405–2413.

https://doi.org/10.1182/blood-2010-07-296244

Published: 2011

Includes: Supplemental data

Journal Articles

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Blood (2010) 116 (21): 992.

https://doi.org/10.1182/blood.V116.21.992.992

Published: 2010

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.

Davide Rossi, MD, Silvia Rasi, PhD, Alberto Fabbri, MD, Francesco Forconi, MD, PhD, Marco Fangazio, MD, Alessio Bruscaggin, PhD, Silvia Franceschetti, MD, Lorenzo De Paoli, MD, Alessia Puma, MD, Ricardo Bruna, MD, Annalisa Chiappella, MD, Enrico M. Pogliani, MD, Francesco Lauria, MD, Umberto Vitolo, MD, Gianluca Gaidano, MD, PhD

Blood (2009) 114 (22): 442.

https://doi.org/10.1182/blood.V114.22.442.442

Published: 2009

Journal Articles

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Blood (2009) 113 (18): 4153–4162.

https://doi.org/10.1182/blood-2008-11-185132

Published: 2009

Includes: Supplemental data

Journal Articles

The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21

Davide Rossi, Silvia Rasi, Silvia Franceschetti, Daniela Capello, Andrea Castelli, Lorenzo De Paoli, Antonio Ramponi, Annalisa Chiappella, Enrico M. Pogliani, Umberto Vitolo, Ivo Kwee, Francesco Bertoni, Annarita Conconi, Gianluca Gaidano

Blood (2008) 112 (11): 480.

https://doi.org/10.1182/blood.V112.11.480.480

Published: 2008

Journal Articles

Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).

Blood (2007) 110 (11): 3432.

https://doi.org/10.1182/blood.V110.11.3432.3432

Published: 2007

Journal Articles

Imatinib concentrations in human milk

Carlo B. Gambacorti-Passerini, Lucia Tornaghi, Elena Marangon, Anna Franceschino, Enrico M. Pogliani, Maurizio D'Incalci, Massimo Zucchetti

Blood (2007) 109 (4): 1790.

https://doi.org/10.1182/blood-2006-10-051391

Published: 2007

Journal Articles

Relationship between Autoimmune Phenomena and Disease Stage and Therapy in B-Cell Chronic Lymphocytic Leukaemia.

Wilma Barcellini, MD, Silvana Capalbo, MD, Rosa M. Agostinelli, MD, Francesca R. Mauro, MD, Achille Ambrosetti, MD, Rossella Calori, MD, Agostino Cortelezzi, MD, Luca Laurenti, MD, Enrico M. Pogliani, MD, Paola Pedotti, MD, Vincenzo Liso, MD, Franco Mandelli, MD, Alberto Zanella, MD

Blood (2006) 108 (11): 4929.

https://doi.org/10.1182/blood.V108.11.4929.4929

Published: 2006

Journal Articles

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Giuseppe Rossi, MD, Enrico M. Pogliani, MD, Emanuele Angelucci, MD, Pietro Fabris, MD, Giorgio Lambertenghi-Deliliers, MD, Paola Polistena, MD, Eros Di Bona, MD, Fabio Ciceri, MD, Franco Leoni, MD, Claudia Minotto, MD, Daniele Mattei, MD, Maurizio Musso, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2005) 106 (11): 1836.

https://doi.org/10.1182/blood.V106.11.1836.1836

Published: 2005

Journal Articles

The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).

Sergio Cortelazzo, MD, Andrea Rossi, MD, Massimo Federico, MD, Andrea Peveri, MD, Stefano Magrini, MD, Maurizio Martelli, MD, Armando Lopez Guillermo, MD, Elena Oldani, BSc, Alessandro Rambaldi, MD, Fausto Rossini, MD, Enrico M. Pogliani, MD, Emanuele Zucca, MD, Annarita Conconi, MD, Mario Busetto, MD, Gianluca Gaidano, MD, Tiziano Barbui, MD, Franco Cavalli, MD

Blood (2005) 106 (11): 927.

https://doi.org/10.1182/blood.V106.11.927.927

Published: 2005

Journal Articles

Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.

Dario Ferrero, MD, Enrico M. Pogliani, MD, Giovanna Rege-Cambrin, MD, Carmen Fava, MD, Giovanna Mattioli, MD, Chiara Dellacasa, MD, Valentina Giai, MD, Mariella Genuardi, Paola Perfetti, MD, Monica Fumagalli, MD, Mario Boccadoro, MD

Blood (2005) 106 (11): 4856.

https://doi.org/10.1182/blood.V106.11.4856.4856

Published: 2005

Journal Articles

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

Francesco Lo-Coco, Giuseppe Cimino, Massimo Breccia, Nélida I. Noguera, Daniela Diverio, Erica Finolezzi, Enrico M. Pogliani, Eros Di Bona, Concetta Micalizzi, Mariagrazia Kropp, Adriano Venditti, Agostino Tafuri, Franco Mandelli

Blood (2004) 104 (7): 1995–1999.

https://doi.org/10.1182/blood-2004-04-1550

Published: 2004

Journal Articles

Therapy of Molecular Relapse in Acute Promyelocytic Leukemia

Francesco Lo Coco, Daniela Diverio, Giuseppe Avvisati, Maria C. Petti, Giovanna Meloni, Enrico M. Pogliani, Andrea Biondi, Giuseppe Rossi, Carmelo Carlo-Stella, Carmine Selleri, Bruno Martino, Giorgina Specchia, Franco Mandelli

Blood (1999) 94 (7): 2225–2229.

https://doi.org/10.1182/blood.V94.7.2225.419k03_2225_2229

Published: 1999

NARROW

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21

Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).

Imatinib concentrations in human milk

Relationship between Autoimmune Phenomena and Disease Stage and Therapy in B-Cell Chronic Lymphocytic Leukaemia.

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).

Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

Therapy of Molecular Relapse in Acute Promyelocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only